Literature DB >> 28495131

Massive intracerebral Epstein-Barr virus reactivation in lethal multiple sclerosis relapse after natalizumab withdrawal.

Barbara Serafini1, Eleonora Scorsi2, Barbara Rosicarelli3, Valérie Rigau4, Eric Thouvenot5, Francesca Aloisi6.   

Abstract

Rebound of disease activity in multiple sclerosis patients after natalizumab withdrawal is a potentially life-threatening event. To verify whether highly destructive inflammation after natalizumab withdrawal is associated with Epstein-Barr virus (EBV) reactivation in central nervous system infiltrating B-lineage cells and cytotoxic immunity, we analyzed post-mortem brain tissue from a patient who died during a fulminating MS relapse following natalizumab withdrawal. Numerous EBV infected B cells/plasma cells and CD8+ T cells infiltrated all white matter lesions; the highest frequency of EBV lytically infected cells and granzyme B+ CD8+ T cells was observed in actively demyelinating lesions. These results may encourage switching to B-cell depleting therapy after natalizumab discontinuation.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Cytotoxic T lymphocytes; Epstein-Barr virus; Histopathology; Multiple sclerosis; Natalizumab; Post-mortem

Mesh：

Substances：

Year:  2017        PMID： 28495131     DOI： 10.1016/j.jneuroim.2017.03.013

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN： 0165-5728            Impact factor:   3.478


  9 in total

1.  Higher EBV response is associated with more severe gray matter and lesion pathology in relapsing multiple sclerosis patients: A case-controlled magnetization transfer ratio study.

Authors:  Dejan Jakimovski; Murali Ramanathan; Bianca Weinstock-Guttman; Niels Bergsland; Deepa P Ramasamay; Ellen Carl; Michael G Dwyer; Robert Zivadinov
Journal:  Mult Scler       Date:  2019-02-13       Impact factor: 6.312

Review 2.  The CD8 T Cell-Epstein-Barr Virus-B Cell Trialogue: A Central Issue in Multiple Sclerosis Pathogenesis.

Authors:  Caterina Veroni; Francesca Aloisi
Journal:  Front Immunol       Date:  2021-07-07       Impact factor: 7.561

Review 3.  B and T Cells Driving Multiple Sclerosis: Identity, Mechanisms and Potential Triggers.

Authors:  Jamie van Langelaar; Liza Rijvers; Joost Smolders; Marvin M van Luijn
Journal:  Front Immunol       Date:  2020-05-08       Impact factor: 7.561

4.  Induction of brain-infiltrating T-bet-expressing B cells in multiple sclerosis.

Authors:  Jamie van Langelaar; Liza Rijvers; Malou Janssen; Annet F Wierenga-Wolf; Marie-José Melief; Theodora A Siepman; Helga E de Vries; Peter-Paul A Unger; S Marieke van Ham; Rogier Q Hintzen; Marvin M van Luijn
Journal:  Ann Neurol       Date:  2019-06-19       Impact factor: 10.422

5.  Epstein-Barr Virus-Specific CD8 T Cells Selectively Infiltrate the Brain in Multiple Sclerosis and Interact Locally with Virus-Infected Cells: Clue for a Virus-Driven Immunopathological Mechanism.

Authors:  Barbara Serafini; Barbara Rosicarelli; Caterina Veroni; Gina Adriana Mazzola; Francesca Aloisi
Journal:  J Virol       Date:  2019-11-26       Impact factor: 5.103

6.  Primary Peripheral Epstein-Barr Virus Infection Can Lead to CNS Infection and Neuroinflammation in a Rabbit Model: Implications for Multiple Sclerosis Pathogenesis.

Authors:  Asma Hassani; Narendran Reguraman; Safa Shehab; Gulfaraz Khan
Journal:  Front Immunol       Date:  2021-11-25       Impact factor: 7.561

7.  Multiple Sclerosis Disease Activity and Disability Following Discontinuation of Natalizumab for Pregnancy.

Authors:  Kerstin Hellwig; Marianne Tokic; Sandra Thiel; Nina Esters; Charlotte Spicher; Nina Timmesfeld; Andrea I Ciplea; Ralf Gold; Annette Langer-Gould
Journal:  JAMA Netw Open       Date:  2022-01-04

8.  Cytotoxic B Cells in Relapsing-Remitting Multiple Sclerosis Patients.

Authors:  Vinícius O Boldrini; Ana M Marques; Raphael P S Quintiliano; Adriel S Moraes; Carla R A V Stella; Ana Leda F Longhini; Irene Santos; Marília Andrade; Breno Ferrari; Alfredo Damasceno; Rafael P D Carneiro; Carlos Otávio Brandão; Alessandro S Farias; Leonilda M B Santos
Journal:  Front Immunol       Date:  2022-02-07       Impact factor: 7.561

Review 9.  Efficacy of Disease Modifying Therapies in Progressive MS and How Immune Senescence May Explain Their Failure.

Authors:  Navid Manouchehri; Victor H Salinas; Negar Rabi Yeganeh; David Pitt; Rehana Z Hussain; Olaf Stuve
Journal:  Front Neurol       Date:  2022-03-31       Impact factor: 4.003
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.